TIZIANA LIFE SCIENCES LTD (TLSA)

BMG889121031 - Common Stock

0.43  +0.01 (+2.38%)

News Image
5 hours ago - InvestorPlace

3 EV Stocks to Buy for the Next Bull Run: March 2024

EV stocks have broadly underperformed the market in 2024, which has, in turn, created a number of opportunities to buy at a bargain.

News Image
23 days ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal...

News Image
2 months ago - InvestorPlace

7 Over-Hyped Stocks to Sell Before They Plunge

It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell.

News Image
3 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...

News Image
3 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 ...

News Image
3 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist...

News Image
3 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...

News Image
4 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...

News Image
4 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...

News Image
5 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

News Image
5 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning!

News Image
5 months ago - Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing...

News Image
5 months ago - TheNewswire.com

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive multiple sclerosis (MS) with intranasal foralumab.

News Image
5 months ago - TheNewswire.com

Tiziana Life Sciences reports six-month PET scan results for MS patients

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced an update on the company's progress in treating non-active secondary progressive multiple sclerosis (MS).

News Image
6 months ago - Seeking Alpha

Tiziana announces positive six-month PET scan results with its intranasal Foralumab

shapecharge Biotech Tiziana Life Sciences (NASDAQ:TLSA) Friday announced that five out of six patients in the FDA-authorized Expanded Access Program showed...

News Image
6 months ago - Tiziana Life Sciences Ltd.

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being...

News Image
6 months ago - Tiziana Life Sciences Ltd.

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes...

News Image
6 months ago - Investor's Business Daily

Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal

Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday.